An Efficient Method for In Vitro Gene Delivery via Regulation of Cellular Endocytosis Pathway

Component: Carrier 1 (Polymer); Description: Branched polyethylenimine (PEI), 25 kDa — "gold standard" for in vitro gene delivery

Component: Carrier 2 (Lipid); Description: Lipofectamine™ 2000 (Lipo2000) — widely used commercial cationic lipid

Component: Plasmid DNA; Description: pEGFP-C1 (enhanced green fluorescent protein reporter); pGL3-control (luciferase reporter)

Component: Standard Protocol (PEI); Description: N/P ratio = 10; DNA:PEI prepared in 250 μL each, mixed, incubated 20 min, diluted to 2 mL; added to cells in 2 mL medium; 4 h incubation

Component: Standard Protocol (Lipo2000); Description: DNA (μg):Lipo2000 (μL) = 1:2.5; complexes prepared similarly; added to cells in medium; 4 h incubation

Component: Modified Protocol; Description: • Remove culture medium completely<br>• Add complexes at reduced volume: 700 μL (6-well) or 300 μL (24-well)<br>• Incubate for 1.5 hours (optimized)<br>• Replace with fresh medium

Component: Complex Concentration; Description: Modified method: ~3.57× higher than standard

Component: Particle Properties; Description: PEI: Size reduced from 88.2 nm (standard) to 65.1 nm (modified); zeta potential unchanged (~23 mV)<br>Lipo2000: Size reduced from 314.5 nm to 146.7 nm; zeta potential unchanged (~18 mV)

Parameter: Cell Lines Tested (10 lines); Details: • Human cancer: Hep G2, SMMC-7721, MCF-7, AGS, HeLa<br>• Mouse cancer: 4T1<br>• Normal/immortalized: NIH/3T3 (mouse fibroblast), C2C12 (mouse myoblast), L6 (rat myoblast)<br>• Embryonic stem cells: R1 (mouse ESC)<br>• Primary cells: Human skin fibroblasts

Parameter: Plate Formats; Details: 6-well (4 μg DNA/well) and 24-well (0.8 μg DNA/well)

Parameter: Cell Confluency; Details: PEI: 70-80%; Lipo2000: 90-95% (per manufacturer recommendations)

Parameter: Transfection Complexes; Details: PEI/pDNA (N/P=10) or Lipo2000/pDNA (1:2.5 ratio); incubated 20 min at RT

Parameter: Incubation Times Tested; Details: 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0 hours (modified); 4 hours (standard)

Parameter: Volumes Tested; Details: 200-900 μL (6-well), 200-500 μL (24-well)

Parameter: Controls; Details: • Untransfected cells (viability baseline)<br>• Standard PEI and Lipo2000 protocols<br>• "Traditional" procedure (medium present, variable complex volume)

Parameter: Replicates; Details: Each experiment performed in triplicate and repeated three times

Analysis Category: Transfection Efficiency (Qualitative); Methods: Inverted fluorescence microscopy (Leica DMI 4000B) for EGFP expression at days 1-2

Analysis Category: Transfection Efficiency (Quantitative); Methods: • Flow cytometry (FACS Calibur): % EGFP+ cells in 1×10⁴ cells; CellQuest software<br>• Luciferase assay: Promega Luciferase Assay System; normalized to total protein (BCA assay); RLU/mg protein

Analysis Category: Cell Viability; Methods: CCK-8 assay (Dojindo); absorbance at 490 nm (reference 630 nm); viability = [(A_sample − A_blank)/(A_control − A_blank)] × 100%

Analysis Category: Intracellular Trafficking; Methods: Confocal laser scanning microscopy (Leica TCS SP5); TOTO-3-labeled pDNA (ex: 642 nm, em: 660 nm); time-lapse imaging every 0.5 h

Analysis Category: Endocytosis Pathway Analysis; Methods: Pharmacological inhibitors (1 h pretreatment):<br>• Chlorpromazine (10 μg/mL) — clathrin-mediated endocytosis<br>• MβCD (5 mM) — caveolae-mediated endocytosis<br>• Amiloride (1 mM) — macropinocytosis

Analysis Category: Particle Characterization; Methods: Malvern Zetasizer Nano ZS90: size and zeta potential at 25°C

Analysis Category: Statistical Analysis; Methods: SPSS 11.5; mean ± SD; P < 0.05 = significant, P < 0.01 = highly significant

Volume: Standard (500 μL complex + 2 mL medium); Transfection Efficiency: Baseline; vs. Standard: 1.0×

Volume: 300 μL; Transfection Efficiency: Moderate; vs. Standard: -

Volume: 500 μL; Transfection Efficiency: High; vs. Standard: -

Volume: 700 μL; Transfection Efficiency: Peak; vs. Standard: ~2.8× higher

Volume: 900 μL; Transfection Efficiency: Decreased; vs. Standard: -

Comparison: Hep G2; Modified: Higher; Traditional: Lower; Significance: P < 0.01

Comparison: NIH/3T3; Modified: Higher; Traditional: Lower; Significance: P < 0.01

Comparison: SMMC-7721; Modified: Higher; Traditional: Lower; Significance: P < 0.01

Comparison: Volume effect in traditional method; Modified: Minimal; Traditional: Slight increase; Significance: -

Parameter: Optimal volume; 6-Well Plate: 700 μL; 24-Well Plate: 300 μL

Parameter: Optimal incubation time; 6-Well Plate: 1.5 hours; 24-Well Plate: 1.5 hours

Parameter: Procedure; 6-Well Plate: Remove medium → add complexes → incubate 1.5 h → replace with fresh medium

Cell Type: Hep G2 (liver cancer); PEI Modified Fold Increase: ~2.8×; Lipo2000 Modified Fold Increase: Significant

Cell Type: SMMC-7721 (liver cancer); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: HeLa (cervical cancer); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: MCF-7 (breast cancer); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: AGS (gastric cancer); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: 4T1 (mouse breast cancer); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: NIH/3T3 (fibroblast); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: C2C12 (myoblast); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: L6 (rat myoblast); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: R1 (mouse ESC); PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Cell Type: Primary fibroblasts; PEI Modified Fold Increase: Significant; Lipo2000 Modified Fold Increase: Significant

Condition: Modified, 0.5 h; Viability vs. Standard: Higher (minimal toxicity); Significance: -

Condition: Modified, 1.0-1.5 h; Viability vs. Standard: Similar to standard; Significance: P > 0.05

Condition: Modified, 2.0+ h; Viability vs. Standard: Lower; Significance: P < 0.05

Condition: Standard with increased concentration (S2); Viability vs. Standard: Dramatically lower; Significance: Most cells died

Complex: PEI-Standard; Size (nm): 88.2 ± 1.3; Zeta Potential (mV): 22.9 ± 2.0

Complex: PEI-Modified; Size (nm): 65.1 ± 2.7 (↓); Zeta Potential (mV): 23.4 ± 3.3 (unchanged)

Complex: Lipo-Standard; Size (nm): 314.5 ± 6.8; Zeta Potential (mV): 17.9 ± 0.9

Complex: Lipo-Modified; Size (nm): 146.7 ± 1.3 (↓); Zeta Potential (mV): 18.7 ± 0.6 (unchanged)

Carrier: PEI; Method: Standard; Clathrin: ✓ Involved; Caveolae: ✓ Involved; Macropinocytosis: ✓ Involved

Carrier: PEI; Method: Modified; Clathrin: ✓ Involved; Caveolae: ✓ Involved; Macropinocytosis: Excluded

Carrier: Lipo2000; Method: Standard; Clathrin: ✓ Involved; Caveolae: ✓ Involved; Macropinocytosis: ✓ Involved

Carrier: Lipo2000; Method: Modified; Clathrin: Excluded; Caveolae: ✓ Involved; Macropinocytosis: ✓ Involved

Time: 0.5 h; Modified Method: Polyplexes attached to membranes; Standard Method: Minimal attachment

Time: 1.0-1.5 h; Modified Method: Penetration into cells; Standard Method: Slow attachment ongoing

Time: 1.5-2.5 h; Modified Method: Dispersed in cytoplasm/nucleus; Standard Method: Penetration begins

Time: 2.5+ h; Modified Method: -; Standard Method: Dispersion begins (~2 h later)

1. Endocytosis inhibitor specificity: The authors acknowledge that "many chemical inhibitors are not specific to a single internalization pathway" and that inhibition may "artificially upregulate other internalization routes." Inhibition experiments were "rationally designed" but remain subject to off-target effects.

2. In vitro only: All experiments performed in cultured cells; no in vivo validation or demonstration of therapeutic gene delivery.

3. Concentration-dependent observations: The modified method increases complex concentration ~3.57-fold; simple concentration increase in standard procedure caused cell death, but the mechanism of why the modified procedure avoids this toxicity while achieving higher efficiency is not fully elucidated.

4. Surface tension artifacts: At 300 μL in 24-well plates, "cells located at the margin of the well had the highest transfection efficiency, but cells in the middle of the well were rarely transfected because this area was only slightly covered by the transfection mixture due to the surface tension." This indicates potential heterogeneity in transfection across the well.

5. Mechanism not fully established: While changes in endocytosis pathways and particle size were observed, the causal relationship between these changes and enhanced transfection efficiency is correlative, not definitively proven.

6. Cell-type variability in optimal conditions: Optimal volumes were established for Hep G2 and may require re-optimization for other cell types (though the method was broadly effective).

7. No comparison to other transfection reagents: Only PEI and Lipo2000 were tested; the authors suggest applicability to other materials but did not demonstrate this.

8. Primary cells limited: Only one primary cell type (skin fibroblasts) was tested; primary cells from other tissues or more difficult-to-transfect primary cells were not evaluated.

9. No long-term expression studies: Transgene expression was assessed at 1-3 days; long-term stability/transgene persistence was not reported.

10. Potential for increased reagent consumption: The modified method uses a higher concentration of complexes; while total DNA amount per well is the same, the effective concentration during transfection is higher, which may increase reagent consumption in scaled-up applications.

Report prepared based on the published International Journal of Nanomedicine article. For full experimental details, supplementary information, and complete references, please refer to the original publication.